Currently the only widely accepted corneal blindness treatment is to replace it by transplantation with human donor cornea. However, increasing shortage of donor corneas as well as high risk of rejection in some corneal diseases remain two major problems, which limit the success of corneal transplantation. Corneal neovascularization is considered as one of the main risk factors of graft failure.
Introduction
Corneal diseases are a major cause of vision loss second to cataracts only in overall importance and affect more than 10 million individuals worldwide 1, 2 . Currently the only widely accepted corneal blindness treatment is transplantation of human donor cornea. The worldwide demand for transplantation corneas exceeds the supply and this situation will worsen with an aging population and increased use of cornea laser surgery 3 . An alternative for corneal transplantation is replacement of the damaged cornea with an artificial substitute -keratoprosthesis. Existing prostheses neither integrate seamlessly into the host tissue, nor promote reinnervation and mainly remains as a last source option 4 .
Phase I human studies performed by Griffith and Fagerholm 5, 6 in Sweden have shown proof-of-concept for the use of biomimetic materials as corneal implants to promote corneal regeneration as an alternative to donor cornea implantation. Implants fabricated from carbodiimide cross-linked collagen were used in this study as corneal substitute for transplantation and stimulated both corneal tissue and nerve regeneration in the patients, without need for immunosuppression. More recently, we have developed more robust formulations, which were already successfully tested in patients with high risk of donor cornea rejection 7 and showed that drugs incorporated into nanoparticles, can be released from these corneal implants 8,9 . This work aims to conquer two big current problems of corneal transplantation. First, developed bioengineered corneal implants can help decrease shortage of human donor corneas, which varies from 30% in developed countries to 80% in developing nations 10, 11 . Even if available and transplanted human donor cornea carries a risk of rejection. Major factors responsible for rejection are significant corneal vessels, previous corneal graft rejection in the operated eye, repeated keratoplasty and previous herpetic eye disease 12, 13 . Current "gold" standard of preventing and treating corneal allograft rejection as well as corneal neovascularization (CN) is topical use of corticosteroids. They have well-known side effects such as increased intraocular pressure and cataract formation. Moreover, effect of corticosteroids on CN is not always sufficient. A number of other agents were also tried to inhibit CN such as general and topical cyclosporine, methotrexate and several others with limited effect and side effects 14 .
Excessive VEGF production along with pro-inflammatory cytokines (e.g. transforming growth factors α and ß1 and fibroblast growth factor) are major driving factors for CN.
A number of monoclonal antibodies and their derivatives (bevacizumab, ranibizumab, aflibercept) against vascular endothelial growth factor (VEGF) are currently in wide clinical use for inhibition of vessel ingrowth in age-related macular degeneration 15 .
They have been also tested as agents to inhibit vessel ingrowth in cornea both before and after corneal transplantation to treat CN and prevent graft failure 14 .
However, due to short half-life of the drugs, to the fact that the required dose, the frequency and repetition of the injection are not still defined, it often leads to only partial reduction of CN and its recurrence. Moreover, response in central CN was less marked, probably due to the lower expression of VEGF in long standing vessels and to the distance from the site of injections with respect to a peripheral CN 14 . It was also shown that bevacizumab suppresses CN more effectively than its derivative ranibizumab 16 .
These facts show the need of new approach to treat corneal blindness where conventional corneal transplantation carries a high risk of rejection. Creating a composite corneal substitute with integrated sustained release system of anti-angiogenic drug might become a valuable alternative to human donor cornea allograft combined with frequent anti-angiogenic drug injections or drops.
Objective of the project was to develop composite corneal implants that will serve a dual purpose of: 1) promoting corneal regeneration as an alternative to allograft transplantation, thereby alleviating the organ shortage problem, and 2) delivering anti-vascular endothelial growth factor (anti-VEGF) to stop vessel ingrowth inside the implant, thus decreasing the risk of implant rejection.
Materials and methods
Bevacizumab (Avastin, La Roche, Switzerland) was used as an anti-VEGF agent throughout the study. All chemicals were purchased from Sigma Aldrich (USA) if not otherwise indicated in the text.
Synthesis of Gold nanoparticles (GNPs)@Bevacizumab
Synthesis of core GNPs: The core GNPs have been synthesized using modified wet-chemical synthesis route as described earlier by Patra et al 17 . Before synthesis of, all the glassware is cleaned with aqua regia (3 HCl:1 HNO3) and autoclaved for metallic and non-metallic decontamination. An aqueous solution of 250 μM chloroauric acid (hydrated HAuCl4) was brought nearly to the boiling temp at 100°C and stirred continuously with a cleaned and metal ion free stirrer. For the reduction, 600 μM freshly prepared trisodium citrate solution was added quickly at once, resulting in a change in reaction mixture color from pale yellow to deep red to orange in the case of smaller size nanoparticles. After generating the persistent color, temperature was brought down to 25°C, and colloidal GNPs solution was stirred for an additional 15 minutes. After stabilizing overnight, the solution was centrifuged stepwise at 5000 rpm to gently precipitate and re-suspend to make a concentrated stock of 1250 μM GNPs. The particles are then characterized by UV visible spectroscopy and Photon Correlation Spectroscopy (PCS) for hydrodynamic properties along with surface zeta potentials (x).
Tethering GNPs@Bevacizumab:
Considering the sensitive nature of the depletion, we have avoided covalent linking of bevacizumab to GNPs and functionalized the gold nanoparticles (GNPs@Bevacizumab) using electrostatic interactions. While functionalizing bevacizumab, we have considered the fact that amino acids, proteins and polypeptides have multiple types of interactions with GNPs including with the peptide backbone apart from all the positively charged residues 18, 19 . Bevacizumab, being a monoclonal antibody (cogitating the isoelectric pH for IgG class ranging from pH 6 to 8) 20 , we choose to trigger the drug in citrate buffer (with pH 5.5) to acquire the net charge positive. GNPs were pre-activated in the same buffer and kept at x >-30mV for maximizing the electrostatic interactions and loading of the bevacizumab on surface of the GNPs. The drug was added gradually and until the surface plasmon of GNPs make a drastic change in colour. According to the plasmonic nature of GNPs, we have found that the range of loading could vary from 1-20 mg/ml with an optimum concentration of 11.11 mg/ml (GNPs@Bevacizumab1). The maximum concentration of Bevacizumab loading can go up to 17.85 mg/ml and assigned as 
Flocculation test
GNPs and GNPs@Bevacizumab were incubated with different concentrations of NaCl solutions (4, 8, 16, 25 and 50 mM) in a 1:1 volume ratio. All the samples were incubated at room temperature for 10 minutes and the hydrodynamic diameter, zeta potential and UV-visible absorbance were measured. 21
Fabrication of collagen scaffold with GNPs@Bevacizumab entrapped
Type I porcine atelocollagen was purchased from Nippon Meat Packers Inc. (Tokyo, Japan). Collagen hydrogel scaffolds were prepared as previously described 5, 6 . Massachusetts, USA) with a DLaTGS detector. The whole system was continuously purged with nitrogen and the IR spectra were acquired at 4 cm -1 resolution. A total of 64 scans were performed between 4400-600 cm -1 . To assess whether fabricated collagen-based hydrogel scaffolds with Bevacizumab release system inhibit cell proliferation, 1 X 10 4 cells were seeded on the top of 6 mm hydrogel disc with incorporated GNPs@Bevacizumab in a 96-well plate and cultured for 48h in BPE-rEGF supplemented KSFM at 37°C in 5% CO2. Blank scaffolds, hydrogels with free drug were also cultured along with HCECs culture without any hydrogel scaffold, which served as control for the experiment. In 48h, the media was aspirated and WST-1 reagent was added to the medium following the manufacturer's instructions. The absorbance was taken at 450 nm in Victor3 V 1420 Multilabel Plate Counter (PerkinElmer, Waltham, MA, USA). Results represent mean values from triplicate measurements.
Cell proliferation assay

Statistical analysis
Difference between groups in Bevacizumab release study and in WST-1 assay was analyzed by Kruskal-Wallis test. A p value<0.05 was considered statistically significant. All the tests were performed on IBM SPSS Statistics 26 and GraphPad Prism 8.
Results
Tethering of Bevacizumab on gold nanoparticles and nanosystem characterization
Bioconjugation of bevacizumab on to GNPs surface was studied by DLS, absorption spectroscopy and TEM as shown in Figure 1a -c. Loading efficiency of bevacizumab on to the surface of GNPs was in the range 1-20 mg/ml, we have fabricated two different loading concentration, 11.11 mg/ml of bevacizumab (GNPs@Bevacizumab1) is the optimum concentration of the drug, which can be effectively tethered on to GNPs. The highest concentration is achievable up to 17.85 mg/ml (GNPs@Bevacizumab2). Figure 1(a) represents DLS profile of bare GNPs, GNPs@Bevacizumab1 and GNPs@Bevacizumab2, surface modified GNPs are in the size range of 20 nm in hydrodynamic diameter. This was further verified by UV visible spectroscopy with absorption maxima at 520, 528 and 535 nm respectively for the synthesized nanomaterials (Figure 1 (b) ). TEM confirmed nanorange of fabricated nanoparticles with sizes between 15-20 nm. Conjugation of GNPs@Bevacizumab was studied in vitro by using salt-induced aggregation study in presence of NaCl as illustrated in Figure 2 a-f. The results depict that the disruption of the electrostatic interaction 22 between GNPs and bevacizumab leading to the formation of large aggregates (Figure 2 
Hydrogel with incorporated GNP@Bevacizumab: optical clarity, release profile and cytotoxicity
Incorporation of GNP@Bevacizumab in hydrogel scaffold during fabrication did not influence the scaffold clarity. Composite graft was strong enough to withstand preparation for cell studies i.e. trephination, handling with forceps, which are similar to handling of corneal graft during surgery (Figure 3) . The sustained release of bevacizumab was obtained with GNP based release system, the drug constantly released up to day 24 both from GNPs not integrated into the hydrogel, and when GNPs@Bevacizumab was incorporated in the hydrogel (Figure 4a-c) . The retention time of the drug increased appreciably when it was conjugated with GNPs and integrated into the hydrogel construct as observed by evaluating the concentration of free bevacizumab in the solution using ELISA (p = 0.197). Incorporation of free bevacizumab into collagen implants allowed getting sustained release of the drug up to day 10. 75% of bevacizumab released on day 1 and 90% of free bevacizumab released by day 5. By comparison, GNP encapsulated bevacizumab within collagen implants showed more smooth and gradual release over 14 days. 65% of the drug released on day 1 and 90% of bevacizumab released by day 10 (Figure 4a ). Figure 4b represents FTIR spectral signature of bevacizumab released from the hydrogels, the FTIR signature provides two relevant findings: (i) Bevacizumab is a monoclonal antibody originally developed for treatment of cancer. 26 Its ability to inhibit vessel ingrowth due to VEGF blockage has made it one of the most popular drugs in treatment of neovascular age-related macular degeneration. 15 The main drawback of the drug is that the achieved effect is time limited and it needs to be introduced at least monthly to maintain the effect. 27 Similar short-term effect of bevacizumab was observed when used for treatment of corneal neovascularization. 28 That is why fabrication of bevacizumab sustained release system is of great interest and several were already developed and tested in vitro and in vivo. [29] [30] [31] Bevacizumab attached to gold nanoparticles using electrostatic interactions proved to be a promising option showing sustained release of the drug for up to 24 days. When this sustained release system was introduced in collagen-based corneal implant it did not cause decrease of optical properties of the composite bioengineered corneal graft due to extremely small size of the particles (15-20 nm). Fabricated implants were strong enough to tolerate preparation for cell studies i.e. trephination, handling with forceps, which are similar to handling of corneal graft during surgery. These composite grafts did not inhibit proliferation of human corneal epithelial cells as well.
At the same time, sustained release of bevacizumab from collagen-based implant was preserved. More interestingly, incorporation of pure bevacizumab into the implant allowed getting sustained release of the drug as well; still the release profile was not as steep as with GNPs@Bevacizumab.
We suggest that application of developed composite corneal substitute can help alleviating or preventing rejection probability when used in vascularised hazy corneas as corneal allograft due to several reasons. First, collagen-based cell-free hydrogel already has shown low immunogenicity when implanted in both animal and human corneas; no systemic immunosuppression was needed even when they were implanted in high-risk cases. [6] [7] [8] Second, sustained release of bevacizumab from transplanted hydrogel can potentially overcome current problems of the drug use in CN, i.e. short half-life of the drug, not defined required dose, the frequency of the injection. Moreover, this gold nanoparticle-based sustained release system of bevacizumab might be a promising tool for treatment of corneal and retinal neovascularisation when it is used for subconjunctival or intravitreal injections and might decrease need for frequent re-injection of the drug to maintain its antiangiogenic effect. These findings need further in vitro and in vivo testing to confirm the suggestions.
In conclusion, we have successfully designed a collagen-based cell-free hydrogel construct with incorporated bevacizumab sustained release system. These constructs are optically clear, strong enough to tolerate surgical handling, non-toxic to corneal epithelial cells and does not influence bevacizumab properties, thus suggesting their suitability, as corneal substitute for application in hazy corneas with neovascularization or high risk of its development. Further in vitro and in vivo animal studies needed to be performed to confirm the feasibility of the said nanoparticle entrapped hydrogel scaffolds and also to confirm their efficacy.
